Digital breast tomosynthesis (DBT) leads to an increase in cancer detection in a large breast cancer screening program, reveal researchers. The results of this study were presented today at the annual meeting of the Radiological Society of North America (RSNA).
Digital mammography is the gold standard for breast cancer screening, but may yield suspicious findings that turn out not to be cancer. These false-positive findings are associated with a higher recall rate, or the rate at which women are called back for additional imaging or biopsy.
Breast Cancer during Pregnancy
Management of breast cancer during pregnancy or pregnancy associated breast cancer requires special consideration to avoid harm to the fetus.
Advertisement
Digital breast tomosynthesis has shown promise at reducing recall rates in all groups of patients, including younger women and women with dense breast tissue. Tomosynthesis is similar to mammography in that it relies on ionizing radiation to generate images of the breast. However, unlike conventional mammography, tomosynthesis allows for three-dimensional (3-D) reconstruction of the breast tissue, which can then be viewed as sequential slices through the breast.
Because DBT technology is relatively new, it is typically used only as a supplemental screening tool, but since October 2011, every patient screened for breast cancer at Hospital of the University of Pennsylvania (HUP) in Philadelphia has been screened using DBT, according to Emily F. Conant, M.D., chief of breast imaging at HUP and the study's lead author.
![Quiz on Breast Cancer]( "Quiz on Breast Cancer")
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a woman who breast-feeds is at a lower risk of developing cancer compared to another who does not .Are these mere old wives tales or is there some truth in it? This quiz on breast cancer has all the details.
"We have used DBT on all of our breast screening patients," Dr. Conant said. "Every patient has had it—we have not selected patients because of their risk or breast density or if they were willing to pay extra. We did not charge extra and were able to provide all of our women with this new technology."
For the study, Dr. Conant and colleagues compared imaging results from 15,633 women who underwent DBT at HUP beginning in 2011 to those of 10,753 patients imaged with digital mammography the prior year. Six radiologists trained in DBT interpretation reviewed the images.
The researchers found that, compared to digital mammography, the average recall rate using DBT decreased from 10.40 percent to 8.78 percent, and the cancer detection rate increased from 4.28 to 5.25 (per 1,000 patients). The overall positive predictive value—the proportion of positive screening mammograms from which cancer was diagnosed—increased from 4.1 percent to 6.0 percent with DBT.
"Our study showed that we reduced our callback rate and increased our cancer detection rate," Dr. Conant said. "The degree to which these rates were affected varied by radiologist. But importantly, the ratio of callback to cancer detection rate improved significantly for our radiologists."
Dr. Conant notes that tomosynthesis is an evolving platform, and researchers are already seeing a significant improvement in important screening outcomes.
"It's the most exciting improvement to mammography that I have seen in my career, even more important than the conversion from film-screen mammography to digital mammography," she said. "The coming years will be very exciting, as we see further improvements in this technology."
Source: Eurekalert
Quiz on Breast Cancer
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a woman who breast-feeds is at a lower risk of developing cancer compared to another who does not .Are these mere old wives tales or is there some truth in it? This quiz on breast cancer has all the details.
Advertisement
"We have used DBT on all of our breast screening patients," Dr. Conant said. "Every patient has had it—we have not selected patients because of their risk or breast density or if they were willing to pay extra. We did not charge extra and were able to provide all of our women with this new technology."
For the study, Dr. Conant and colleagues compared imaging results from 15,633 women who underwent DBT at HUP beginning in 2011 to those of 10,753 patients imaged with digital mammography the prior year. Six radiologists trained in DBT interpretation reviewed the images.
The researchers found that, compared to digital mammography, the average recall rate using DBT decreased from 10.40 percent to 8.78 percent, and the cancer detection rate increased from 4.28 to 5.25 (per 1,000 patients). The overall positive predictive value—the proportion of positive screening mammograms from which cancer was diagnosed—increased from 4.1 percent to 6.0 percent with DBT.
"Our study showed that we reduced our callback rate and increased our cancer detection rate," Dr. Conant said. "The degree to which these rates were affected varied by radiologist. But importantly, the ratio of callback to cancer detection rate improved significantly for our radiologists."
Dr. Conant notes that tomosynthesis is an evolving platform, and researchers are already seeing a significant improvement in important screening outcomes.
"It's the most exciting improvement to mammography that I have seen in my career, even more important than the conversion from film-screen mammography to digital mammography," she said. "The coming years will be very exciting, as we see further improvements in this technology."
Source: Eurekalert
Breast Self Examination - Animation
Slides and animation of Breast Self Examination for early detection of breast cancer lumps in women
Advertisement
 Biocon to Maket Its New Drug for Breast CancerBiocon Ltd, a leading biotech firm has now received a regulatory approval to market a drug jointly developed with US-based pharma company Mylan that may help treat breast cancer | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable